+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015

  • ID: 3215942
  • Report
  • March 2015
  • 67 pages
  • Global Markets Direct
1 of 5
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015

Summary:

This, ‘Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015’, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:

- The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Interstitial Cystitis (Painful Bladder Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Interstitial Cystitis (Painful Bladder Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Purchase:

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Interstitial Cystitis (Painful Bladder Syndrome) Overview
Therapeutics Development
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development
Afferent Pharmaceuticals, Inc.
Allergan, Inc.
Aquinox Pharmaceuticals Inc.
Kytogenics Pharmaceuticals, Inc.
Lipella Pharmaceuticals, Inc.
Qu Biologics Inc.
Urigen Pharmaceuticals, Inc.
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(lidocaine + heparin) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AF-219 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AQX-1125 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GM-1111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NEO-5024 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A liposomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QBECP-SSI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interstitial Cystitis (Painful Bladder Syndrome) - Recent Pipeline Updates
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones
Featured News & Press Releases
Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219
Jul 23, 2013: Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis
Apr 02, 2013: Taris Doses First Patient In Second Phase II Clinical Study Of LiRIS For Treatment Of Interstitial Cystitis
Nov 30, 2011: TARIS Initiates Phase II Clinical Study With LiRIS In Interstitial Cystitis Patients
Jun 30, 2011: Urigen Provides Development Update For URG101
Mar 09, 2011: TARIS Initiates Clinical Study In Interstitial Cystitis Patients
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2015
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan, Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Qu Biologics Inc., H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H1 2015
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2015
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
- Afferent Pharmaceuticals, Inc.
- Allergan, Inc.
- Aquinox Pharmaceuticals Inc.
- Kytogenics Pharmaceuticals, Inc.
- Lipella Pharmaceuticals, Inc.
- Qu Biologics Inc.
- Urigen Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll